Talwar Ankoor A, Shulkin Jared M, Hitchner Michaela, McAuliffe Phoebe B, Desai Abhishek A, Broach Robyn B, Percec Ivona
Division of Plastic Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Aesthet Surg J. 2022 Sep 14;42(10):1194-1204. doi: 10.1093/asj/sjac171.
Over the last 2 decades, both invasive and minimally invasive aesthetic procedures have proliferated. Aesthetic surgeons often recommend injectable treatments after cosmetic facial surgery for multiple reasons. However, literature is lacking on how cosmetic surgery affects postoperative facial injectable use.
The aim of this study was to identify predictors of facial injectable use after cosmetic facial surgery.
All adult patients operated on by a single surgeon between 2013 and 2021 were retrospectively reviewed. Patients who had any of the following cosmetic facial surgeries were included: rhytidectomy, blepharoplasty, rhinoplasty, or genioplasty. Patient demographics, clinical history, intraoperative factors, and use of cosmetic facial injectables (neurotoxin, facial fillers, deoxycholic acid, poly-l-lactic acid) were recorded.
A total of 227 patients who underwent facial cosmetic surgery were reviewed, of whom 158 were included. Of these, 89 patients had rhytidectomy (56.3%), 112 had blepharoplasty (70.9%), 28 had rhinoplasty (17.7%), and 7 had genioplasty (4.4%). Injectables were administered to 44.3% of patients after their surgery (n = 73), compared with only 17.7% before surgery (n = 28) (P < 0.001). The most common postoperative injectables were neurotoxins (48.5%) and facial fillers (46.0%), followed by deoxycholic acid (2.7%) and poly-l-lactic acid (2.7%). Multivariate regression revealed factors positively correlated with future injectable use were index blepharoplasty or rhinoplasty, and history of preoperative neurotoxin injection (P < 0.05).
Cosmetic facial injectables are an important consideration in achieving and maintaining optimal facial aesthetics. Their use, especially neurotoxins and facial fillers, has increased among patients postoperatively. These results highlight the contribution of injectable procedures in the context of multidimensional care for augmenting facial aesthetics.
在过去20年中,侵入性和微创美容手术都迅速增加。出于多种原因,美容外科医生经常在面部整形手术后推荐注射治疗。然而,关于整形手术如何影响术后面部注射治疗的文献尚缺。
本研究的目的是确定面部整形手术后面部注射治疗使用的预测因素。
对2013年至2021年间由单一外科医生进行手术的所有成年患者进行回顾性研究。纳入接受以下任何一种面部整形手术的患者:除皱术、眼睑成形术、隆鼻术或颏成形术。记录患者的人口统计学、临床病史、术中因素以及面部美容注射剂(神经毒素、面部填充剂、脱氧胆酸、聚左旋乳酸)的使用情况。
共对227例接受面部整形手术的患者进行了评估,其中158例被纳入研究。其中,89例患者接受了除皱术(56.3%),112例接受了眼睑成形术(70.9%),28例接受了隆鼻术(17.7%),7例接受了颏成形术(4.4%)。44.3%的患者在术后接受了注射治疗(n = 73),而术前只有17.7%的患者接受了注射治疗(n = 28)(P < 0.001)。最常见的术后注射剂是神经毒素(48.5%)和面部填充剂(46.0%),其次是脱氧胆酸(2.7%)和聚左旋乳酸(2.7%)。多因素回归分析显示,与未来注射治疗使用呈正相关的因素是初次眼睑成形术或隆鼻术以及术前神经毒素注射史(P < 0.05)。
面部美容注射剂是实现和维持最佳面部美学效果的重要考虑因素。患者术后对其使用,尤其是神经毒素和面部填充剂的使用有所增加。这些结果凸显了注射治疗在增强面部美学的多维度护理中的作用。